The Celigo Image Cytometer has been previously used for a wide range of immuno-oncology and immunotherapy studies, demonstrating the great utility of this instrument to assess the activity of cytotoxic immune cells against malignant cells of interest.
Sangivamycin is an unsuccessful anti-cancer drug candidate that has proven to be a potent inhibitor of multiple viruses. The authors of this study hypothesized that this compound would also be active against SARS-CoV-2.
Starting with a bioinformatics approach using publicly available databases, the authors were able to confirm that tissues from patients with lung adenocarcinoma had increased expression of BCCIP and that high expression levels of BCCIP were correlated with poor patient prognosis.
Solid tumor biology has become a critical step in accessing the potency of many cancer drugs. 3D spheroids and organoids can provide measurements such as size differences under drug conditions or metabolism and diffusion rates critical to drug development.
The development of targeted molecular therapies is an increasingly popular approach to combat and overcome the limitations of conventional treatments.
A fundamental understanding of the molecular mechanisms responsible for the development and progression of RCC will be pivotal in developing next-generation treatment protocols to improve patient outcomes.
Because there is no certified reference material to determine cell concentration, ISO cell counting standards are a valuable tool for evaluating and selecting fit-for-purpose cell counting methods.
The ongoing pursuit of novel anti-cancer therapeutics must consider the potential for off-target effects on the immune system.
The researchers in this study first utilized various techniques to explore the role of MEX3A in glioma, including immunohistochemistry to assess MEX3A expression levels in glioma tissues, knockdowns of MEX3A in conjunction with a transwell assay to assess migration and an in-vivo mouse model of tumor burden.
The severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused the ongoing COVID-19 pandemic, infecting more than 206 million people and causing upwards of 4.34 million deaths at the time of writing.